Structure and interactions of the human programmed cell death 1 receptor.

Cheng X, Veverka V, Radhakrishnan A, Waters LC, Muskett FW, Morgan SH, Huo J, Yu C, Evans EJ, Leslie AJ, Griffiths M, Stubberfield C, Griffin R, Henry AJ, Jansson A, Ladbury JE, Ikemizu S, Carr MD, Davis SJ. · 2013

Read Structure and interactions of the human programmed cell death 1 receptor. by Cheng X, Veverka V, Radhakrishnan A, Waters LC, Muskett FW, Morgan SH, Huo J, Yu C, Evans EJ, Leslie AJ, Griffiths M, Stubberfield C, Griffin R, Henry AJ, Jansson A, Ladbury JE, Ikemizu S, Carr MD, Davis SJ. (2013) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3636866.txt.

Introduction

A brake on white blood cells, the PD-1 receptor, is mapped in a 2013 article in The Journal of Biological Chemistry by Xiaoxiao Cheng and a large team of co-authors. PD-1 sits on cell surfaces and can slow immune attack when it binds two partner proteins, PD-L1 and PD-L2. How that grip works, at the level of shape, was still unclear.

Using a magnet-based method that maps molecular shape, plus binding and heat tests, the team worked out how PD-1 is built and how each partner binds. The two partners bind in unlike ways and far more weakly than most had thought. Yet weak grips still switch on strong stop signals. That point shapes how new immune drugs are thought about, since many such drugs aim at this same brake.

Catalog record

CREATORCheng X, Veverka V, Radhakrishnan A, Waters LC, Muskett FW, Morgan SH, Huo J, Yu C, Evans EJ, Leslie AJ, Griffiths M, Stubberfield C, Griffin R, Henry AJ, Jansson A, Ladbury JE, Ikemizu S, Carr MD, Davis SJ.
YEAR2013
COLLECTIONPAPERS
FORMATTXT
FILE SIZE69 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3636866

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Structure and Interactions of the Human Programmed Cell Death 1 Receptor* By Xiaoxiao Cheng, Vaclav Veverka, Anand Radhakrishnan, Lorna C Waters, Frederick W Muskett, Sara H Morgan, Jiandong Huo, Chao Yu, Edward J Evans, Alasdair J Leslie, Meryn Griffiths, Colin Stubberfield Published in: The Journal of Biological Chemistry DOI: 10.1074/jbc.M112.448126 ABSTRACT Background: The inhibitory leukocyte receptor PD-1 binds two ligands, PD-L1 and PD-L2. Results: Nuclear magnetic resonance analysis and rigorous binding and thermodynamic measurements reveal the structure of, and the mode of ligand recognition by, PD-1. Conclusion: PD-L1 and PD-L2 bind differently to PD-1 and much more weakly than expected. Significance: Potent inhibitory signaling can be initiated by weakly interacting receptors. Keywords: Cell Surface Protein, Nuclear Magnetic Resonance, Receptors, Signaling, Surface Plasmon Resonance (SPR), Affinity, Complex Formation, Thermodynamics INTRODUCTION In recent years, PD-1 (programmed cell death 1) has emerged as one of the most important inhibitory molecules in the immune system. Its potent inhibitory activity became evident when mice ablated at the Pdcd1 locus developed strain-specific autoimmunity: sporadic glomerulonephritis on a C57BL/6 background (1) and cardiomyopathy in BALB/c mice (2). Genetic studies in humans also emphasize its importance insofar as PDCD1 gene polymorphisms were found to confer susceptibility to systemic lupus erythematosus, atopy, and rheumatoid arthritis (3–5). PD-1 is also responsible for the “exhausted” phenotype of antigen-specific T cells in animal models of chronic infection (6, 7) and in human immunodeficiency (8) and hepatitis (9, 10) virus infections (although the latter is disputed (11)). It has also been implicated in the de novo generation of regulatory T cells (12). Such effects have made PD-1 one of the most actively studied therapeutic targets in cancer immunotherapy; presently, four anti-PD-1 antagonists are in clinical trials (reviewed in Ref. 13). It is suggested that PD-1 inhibits signaling, in T cells at least, by recruiting the phosphatase SHP-2 to TCR4 microclusters during the early stages of immunological synapse formation, where it blocks on-going TCR signaling (14). PD-1 expression is induced upon the activation of CD4+ T cells, CD8+ T cells, NKT cells, B cells, and monocytes (15), whereupon it binds two distinct ligands, PD-L1 (B7-H1 or CD274 (16, 17)) and PD-L2 (B7-DC (18, 19). PD-L1 is both constitutively and inducibly expressed by T and B cells, dendritic cells (DCs), macrophages, mesenchymal stem cells, and bone marrow-derived mast cells and on nonhematopoietic cells; PD-L2 expression is up-regulated on DCs, macrophages, and mast cells (reviewed in Ref. 15). PD-1 is a monomeric type I surface glycoprotein consisting of a single V-set immunoglobulin superfamily (IgSF) domain attached to a transmembrane domain and a cytoplasmic domain with two tyrosine-based signaling motifs. PD-1 is often assigned to the CD28 receptor family, mostly on the basis of functional similarities (e.g. see Ref. 20). However, PD-1 actually shares more structural homology with antigen receptors and CD8 and can be considered to be intermediate between the antigen receptors and CD28 family proteins, suggesting that a PD-1-like protein was a precursor of IgSF family signaling receptors (21). Like the ligands of CD28 and CTLA-4, PD-L1 and PD-L2 are B7 family proteins comprised of tandem V-set and C1-set IgSF domains. In addition to PD-1, PD-L1 binds B7-1, one of the ligands of CD28 and CTLA-4 (22, 23), potentially interlocking the PD-1 and CD28/CTLA-4 signaling pathways. Structures of mouse PD-1 complexed with human PD-L1 (24) and mouse PD-L2 (25) revealed that these proteins interact largely orthogonally via their GFCC′C″ β-sheets. The complex of mouse PD-1 and human PD-L1 (24) is highly reminiscent of V-set domain dimers in antigen receptors, suggesting how in trans interacting receptors could have evolved into in cis interacting IgSF dimers, or vice versa (21, 26). Despite its considerable immunotherapeutic potential, we know relatively little about the structure and interactions of human PD-1. There are no published structures of ligand-bound or unbound forms of the receptor, and whereas relatively high avidities have been measured for the interactions of bivalent forms of PD-1 with its ligands (reviewed in Ref. 15), there have been no systematic measurements of the true affinities. Here, we present the structure of a soluble form of human PD-1 and map its interactions with PD-L1 and PD-L2 using nuclear magnetic resonance (NMR)-based approaches. The new structure helps to account for the distinct affinity and thermodynamic properties of PD-1 binding to PD-L1 and PD-L2. Measurements of the human and mouse affinities suggest that potent inhibitory signaling can be mediated by surprisingly weak interactions. Finally, we use simulations of signaling complex formation to explore the reasons why PD-1 might have two distinct ligands and to gauge the impact of PD-L1 binding to B7-1. EXPERIMENTAL PROCEDURES Expression and Purification of PD-1 and Its Ligands The extracellular region of the mature form of human PD-1 (hPD-1; residues 14–130), with a Met added to the N terminus and a Cys to Ser mutation introduced at position 73 to aid expression and folding, was expressed in the form of untagged protein in inclusion bodies in Escherichia coli BL21 (DE3) pLysS cells using a modified pET vector (Novagen). Uniformly 15N-, 15N/13C-, and 2H/13C/15N-labeled hPD-1 was produced from cells grown in minimal medium containing [15N]ammonium sulfate and d-[13C]glucose, if required, as the sole nitrogen and carbon sources, and 100% D2O when appropriate. Refolding conditions were determined using the iFOLD System 2 Screen (Merck). The hPD-1-expressing cells were resuspended in 50 mm Tris-HCl, 50 mm NaCl, 1 mm Tris(hydroxypropyl)phosphine, 0.5 mm EDTA, 5% glycerol, pH 8.0, before passing twice through a cell disrupter at 30,000 p.s.i. The lysate was made up to 125 mm with non-detergent sulfobetaine 201 (Sigma) and mixed. The hPD-1-containing inclusion bodies were washed once with the above buffer containing 125 mm non-detergent sulfobetaine 201 and then three times with the same buffer without non-detergent sulfobetaine 201. Inclusion bodies were solubilized in 50 mm Tris-HCl, 200 mm NaCl, 2 mm EDTA, 6 m guanidine HCl, pH 8.0. hPD-1 was subsequently efficiently refolded by rapid dilution into 50 mm HEPES, pH 7.5, 500 mm l-arginine, 9 mm glutathione, 1 mm glutathione disulfide, 24 mm NaCl, 1 mm KCl. The refolding mixture was then concentrated by tangential flow filtration, and the refolded protein was purified using a 16/60 Superdex 200 gel filtration column (GE Healthcare). The authenticity of the refolded hPD-1 material was assessed by the comparison of its 1H NMR spectrum with the data obtained for the protein produced in a eukaryotic expression system. Unlabeled, soluble His6-tagged, and biotinylatable forms of human and mouse PD-L1 (hPD-L1 and mPD-L1) and PD-L2 (hPD-L2 and mPD-L2) were produced via stable expression in Chinese hamster ovary (CHO) cells, using approaches used previously (27–29). NMR Spectroscopy NMR spectra were acquired from 0.35-ml samples of 0.5 mm free hPD-1 and 0.2 mm hPD-1·hPD-L1 or hPD-1·hPD-L2 complex in a 25 mm sodium phosphate, 100 mm sodium chloride buffer at pH 6.4, containing 5% D2O, 95% H2O. All of the NMR data were collected at 25 °C on either 600- or 800-MHz Bruker Avance spectrometers equipped with triple resonance (15N/13C/1H) cryoprobes. A series of double and triple resonance spectra were recorded to determine essentially complete sequence-specific resonance assignments for hPD-1, as described previously (30–32). 1H-1H distance constraints required to calculate the structure of hPD-1 were derived from NOEs identified in NOESY, 15N/1H NOESY-HSQC, and 13C/1H

Read the complete text